← Eichor
Condition: Hematologic Malignancy Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Hematologic Malignancy

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment
Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07585760A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combine
Phase 2 · 2 location(s) · Franziska Wachter · NCT05796570CXCR4-targeted PET/CT Imaging in Hematological Malignancies
NA · 1 location(s) · Zhongnan Hospital · NCT05255926First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia
Phase 1 · 4 location(s) · Allterum Therapeutics, Inc · NCT07586618Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
Phase 1 · 13 location(s) · Stelexis BioSciences · NCT06533761A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell
Phase 1 · 14 location(s) · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharm · NCT07179679Mitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple Myeloma
Phase 1/Phase 2 · 1 location(s) · Affiliated Hospital of Nantong University · NCT06246162Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
Phase 2 · 1 location(s) · Shenzhen University General Hospital · NCT07563179Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Do
Phase 1 · 5 location(s) · Celyad Oncology SA · NCT04167696Collection of Samples and Clinical Data From Patients With Amyloid Diseases
Phase N/A · 1 location(s) · Boston Medical Center · NCT00898235Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
Phase 1/Phase 2 · 21 location(s) · Technische Universität Dresden · NCT04385290Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse
Phase 2 · 1 location(s) · Larysa Sanchez · NCT06827860Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
Phase 2 · 4 location(s) · Inhye Ahn · NCT06333262Vertebroplasty With Radiation Therapy for Spine Metastatic Cancer Patients With Indeterminate Lesion (SINS Criteria)
NA · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT05178472A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodyspl
Phase 1/Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT06548230Efficacy of Integrated Induction-Consolidation Chemotherapy and Transplantation for Adult Acute Myeloid Leukemia: Multic
Phase 2 · 1 location(s) · Shanxi Bethune Hospital · NCT07108530Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia
Phase N/A · 14 location(s) · University Hospital, Clermont-Ferrand · NCT05246345CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
Phase 1 · 1 location(s) · Mayo Clinic · NCT04892277A Safety and Efficacy Study of CD-19 t-haNK in Patients With B-cell Acute Lymphoblastic Leukemia
Phase 1 · 2 location(s) · ImmunityBio, Inc. · NCT07556757Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marr
Phase 1/Phase 2 · 2 location(s) · National Cancer Institute (NCI) · NCT04959175Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers
Phase 2 · 10 location(s) · Fred Hutchinson Cancer Center · NCT03779854HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy
Phase 2 · 3 location(s) · Children's Hospital Medical Center, Cincinnati · NCT02143830Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients
Phase 2 · 1 location(s) · The First Affiliated Hospital of Soochow University · NCT06379360Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04216524A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML).
Phase N/A · 1 location(s) · Pfizer · NCT06297161Tumors and Respiratory System Diseases Due to Air Pollution: New Biomarkers of Exposure and Effects
Phase N/A · 3 location(s) · IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06800586TGRX-678 US Phase I for Subjects with Refractory or Advanced Chronic Myelogenous Leukemia
Phase 1 · 2 location(s) · Shenzhen TargetRx Co., Ltd. · NCT06088888A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Maligna
EARLY_Phase 1 · 1 location(s) · Zhejiang University · NCT04532203Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM
Phase 1/Phase 2 · 1 location(s) · Institute of Hematology & Blood Diseases Hospital, China · NCT07109323Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residu
Phase 2 · 1 location(s) · Yehui Tan · NCT07023588
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.